Compare

Minimed Group/$MMED

1D1W1M3M6MYTD1Y5YMAX

About Minimed Group

While MiniMed recently became an independent company again, it began in the 1980s as an upstart pioneer in developing and commercializing insulin pump therapy. Medtronic acquired MiniMed in 2001 and then spun it out in 2026 (though Medtronic still owns roughly 90% of MiniMed shares, which will be relayed to its shareholders as a tax-free distribution in the foreseeable future). MiniMed is the leader in traditional, tubed insulin pumps and also offers continuous glucose monitors, smart insulin pens, and other consumables.
Ticker
$MMED
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Northridge, United States
Website
www.minimed.com

Minimed Group Metrics

BasicAdvanced
$5.1B
-
-$1.19
-
-

What the Analysts think about Minimed Group

Analyst ratings (Buy, Hold, Sell) for Minimed Group stock.
Analyst projections of the future price of Minimed Group stock.

Bulls say / Bears say

MiniMed Flex appears to be improving US pump momentum: US new pumps sold rose more than 20% year on year in the first quarter, and US sales growth accelerated to 13%. The company raised its FY27 organic revenue growth outlook to about 10.5%. (MiniMed)
Growth is not limited to the US: international sales rose 17% organically in the first quarter, supported by expanded sensor supply and the European launch of Abbott-made Instinct sensors. This gives MiniMed another route to grow alongside its US product launches. (MiniMed)
MiniMed has several potential product catalysts beyond Flex, including its FDA-submitted Fit patch pump and a completed US pivotal-trial enrolment for its Vivera fully closed-loop algorithm. The company expects Fit to launch in the US in summer 2027 and Vivera in the second half of 2027, if development and regulatory plans stay on track. (MiniMed)
Profitability and cash generation remain weak during the transition: MiniMed reported a 9.9% adjusted EBITDA margin and used $90 million of free cash in the first quarter. It attributed $111 million of cash outflow to separation and stand-up costs, so the improvement depends partly on those expenses easing. (SEC)
MiniMed faces intense competition in pumps and glucose monitors, while lower-cost CGMs could add pressure to pricing and margins. That may make it harder to convert rapid sales growth into stronger profits. (SEC)
Pump-related litigation remains a material uncertainty: MiniMed disclosed 28 US lawsuits covering 109 individuals, as well as potential claims from roughly 2,000 additional claimants. The company says it cannot predict the proceedings’ timing or ultimate impact. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

Minimed Group Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Minimed Group Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Minimed Group News

AllArticlesVideos

Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure

Barrons4 weeks ago

Squeeze Watch: 10 Stocks With Over 33% Short Interest

Benzinga1 month ago

These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

Benzinga2 months ago

Funds containing Minimed Group

Funds
Fund name
Fund size
$MMED weighting
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.18%
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.18%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.